Fitch Confirms Rating of Regional Electrical Power Networks at 'BB'

Electric vehicle manufacturer Ather Energy announced on Tuesday that it has successfully raised ₹1300 crore through a Qualified Institutional Placement (QIP). This placement was launched on July 15 as part of a larger capital infusion plan amounting to ₹2500 crore.

Investor Response to the Placement

The offering received a positive response from both foreign and domestic institutional investors. Leading Foreign Institutional Investors (FIIs) participating included ADIA, White Oak, and William Blair. Domestic Institutional Investors (DIIs) involved were HDFC Mutual Fund, Axis Mutual Fund, and Edelweiss Mutual Fund, the company reported.

Deal Details and Market Confidence

Ather Energy completed the closure of the ₹1300 crore QIP by issuing 1.08 crore shares at a price of ₹1202 per share. This outcome indicates high investor confidence in the company. The company specified that the raised capital will be directed towards supporting Ather's growth initiatives, including production expansion and new product development, as well as strengthening institutional investor trust in the company's long-term development strategy.

Management Comments

The QIP deal, which closed on Monday, was oversubscribed eight times, and the transaction occurred at a premium to the trading price. This phenomenon demonstrates immense faith from shareholders and investors in the company. Co-founder and CEO of Ather Energy, Tarun Mehta, noted this in an X post on Tuesday. Mehta added that he, along with many existing company partners, including co-founder Swapnil, is also investing in a larger funding round at this stage of Ather's development.

US President Donald Trump has proposed a phased plan to introduce tariffs on imported generic drugs, which could reach 200% by 2028, aiming to stimulate American production. This move is significant for the Indian pharmaceutical industry and bilateral trade.

Details of the Tariff Plan

Under the proposal, generic medicines imported into the US will be subject to zero tariffs for two years, starting August 1st. After this, the zero-tariff period will be extended for another year, after which the rate will increase to 100%, eventually reaching 200% in August 2029. This phased structure is intended to give pharmaceutical companies time to relocate manufacturing capacity to the US before punitive duties take effect.

Trump stated in a post on Truth Social that this measure aims at 'bringing generic drug manufacturing back to America,' penalizing companies that fail to build factories and equipment within the specified period.

Reasons for the Measures and Market Impact

This announcement is part of Trump's broader strategy to bring pharmaceutical manufacturing back to the US and reduce dependence on foreign supply chains. According to Trump, the policy's goal is to protect US citizens, while policies regarding patented, branded, and innovative drugs will remain unchanged.

Trump has repeatedly argued that the US pays significantly more for medications than many other countries and has sought to address accessibility issues by reforming the pharmaceutical sector. This issue has gained political importance ahead of the 2026 US midterm elections. Previously, in April 2025, his administration initiated an investigation under national oversight of pharmaceutical imports according to Section 232 of the Trade Expansion Act. In April of this year, Trump signed an executive order tightening tariffs to 100% on imported branded pharmaceutical products, provided manufacturers agree to government price agreements or commit to producing in the US.

Consequences for Indian Exports

The immediate impact on Indian pharmaceutical exports is likely to be limited due to the proposed two-year tariff-free period. This transition period allows Indian manufacturers to review their supply chains, export strategies, and potential investments in US production. However, the projected increase to 100% and ultimately 200% tariffs could eventually affect Indian exporters who do not establish a local manufacturing base.

India is one of the largest suppliers of generic drugs to the US. Pharmaceuticals account for one of India's top three exports to the United States, amounting to $10.5 billion in 2024-25, according to government data. Indian generics constitute nearly 40% of volume prescriptions in the US market, making the sector particularly vulnerable to sharp tariff increases.

India is also a leading supplier of finished generic dosage forms to the American market. Analyses based on data from the US Food and Drug Administration and trade data estimate that Indian manufacturers provide about 40-50% of total generic prescriptions in the United States. Thus, the proposed tariffs could significantly affect India's pharmaceutical exports if companies do not localize production.

According to Bloomberg, it remains unclear what portion of Trump's proposed tariff burden Indian pharmaceutical companies will ultimately face. Drug tariffs could negatively impact over 40% of India's exports to the US. Previous threats by Trump also jeopardized several commonly prescribed drugs from India, including contraceptives and medications for hypertension and depression. Regarding birth control pills, Bloomberg reported that approximately 65% of prescriptions filled in the US in 2024 were produced by two Indian manufacturers—Glenmark Pharmaceuticals and Lupin.

Broader Trade Context

The pharmaceutical sector is also facing broader trade uncertainty. Jamieson Green, a representative of the US Chamber of Commerce, indicated that the Trump administration may soon introduce new trade measures against about 60 economies, including India, on allegations related to forced labor imports. Washington has proposed an additional 12.5% tariff on imports from India as part of this investigation, although a final decision has not been announced.

Impact on the Indian Economy

Beyond pharmaceuticals, Trump's tariff measures have put pressure on several export-oriented sectors in India. Labor-intensive industries such as textiles and apparel, precious metals and jewelry, leather and footwear, chemicals, engineering goods, and auto components remain most vulnerable due to their reliance on the US market.

According to a Times of India report, although exporters noted increased demand from American buyers in recent weeks, uncertainty regarding potential US tariff measures has delayed the signing of firm orders. Buyers have postponed purchases pending greater clarity on Washington's trade policy. It is reported that sectors including chemicals, textiles, carpets, and leather have attracted greater interest from US buyers, though this has not yet resulted in significant contracts.

Government data showed that India's exports to the US decreased by 1.21% year-on-year to $8.17 billion in June, while imports rose by 33.86% to $5.5 billion.

Current State of Negotiations

India and the US have been negotiating a bilateral trade agreement for several months as both countries seek to deepen trade and investment ties. These negotiations have gained more significance amid expectations of new US tariff announcements at the end of this month.

The government recently informed Parliament that it is closely monitoring all developments and continuing engagement with the US administration. India's Minister of Commerce and Industry, Piyush Goyal, held high-level meetings with US Chamber of Commerce representative Jamieson Greer regarding a comprehensive trade agreement. Although Goyal dismissed reports that India was waiting for better terms, he emphasized that India and the US are actively negotiating, and New Delhi will not concede on its core interests in any trade pact.

In February, Trump announced a temporary trade agreement with India that eased tariff tensions by lowering US rates on Indian goods from an effective 50% to 18%. The agreement also suspended a proposed additional 25% tariff related to India's purchases of Russian oil and reduced mutual tariff rates from 25% to 18%. In return, India agreed to lower or eliminate tariffs on a range of American industrial, agricultural, and consumer goods, with both sides committing to continue negotiations on a broader bilateral trade agreement.

Later, the mutual tariffs ceased to apply following a US Supreme Court ruling on February 20th, which invalidated them. Nevertheless, a 10% tariff remains in place on certain goods from all countries under Section 122 of the US Trade Act of 1974.

Brent crude oil prices exceeded $90 a barrel on Tuesday following the resumption of tensions between the United States and Iran, which heightened inflation risks. Economists warn that the South African Reserve Bank may decide on a further interest rate hike.

Global Market Reaction

The renewed conflict between the US and Iran returned global markets to a risk-off mode on Tuesday. Brent crude reached $90.37 a barrel in the afternoon as investors assessed the potential impact of prolonged supply disruptions through the Strait of Hormuz.

The sharp rise in energy prices intensified inflation concerns both globally and in South Africa. This drew increased attention to the Monetary Policy Committee (MPC) meeting of the South African Reserve Bank (SARB) scheduled for Thursday, where economists are divided on another rate hike.

Conflict Situation Analysis

Patrick Buthelezi, an economist at Sanlam Investments, noted that the resumption of hostile actions added another layer of uncertainty to an already fragile global economy. He stated that the renewed tension calls into question the June memorandum of understanding between the US and Iran, emphasizing that the situation remains unstable despite open diplomatic channels.

According to Buthelezi, the conflict has already begun to disrupt commercial shipping routes and reversed the decline in oil prices observed after previous diplomatic efforts. Although oil prices have risen significantly, they remain below the peak levels reached during the height of the conflict. However, he added that a protracted conflict will ultimately affect reserves that have served as a buffer against supply disruptions.

Impact on Economic Growth

Buthelezi also pointed out that higher energy costs and escalating trade tensions threaten to slow global economic growth, despite the continued resilience of AI-driven investments. He noted that global growth is supported by strong demand for artificial intelligence and its continuous adoption, but this year it will be tested not only by higher energy prices but also by increased trade tariffs.

Although South Africa continues to benefit from economic reforms and relatively favorable trade conditions, Buthelezi forecasts a moderate pace of growth. He believes that progress in economic reforms and favorable trade conditions in South Africa partially offset the pressure caused by rising energy prices and US tariffs, but economic growth is likely to remain moderate.

Central Bank Positions

He also suggested that central banks worldwide will remain cautious, monitoring inflation risks associated with rising oil prices. He believes that the US Federal Reserve will likely maintain a hawkish stance and may raise interest rates even further, as inflation has remained above the 2% target since 2021.

Locally, Buthelezi expects the Reserve Bank to continue tightening monetary policy. He posits that SARB is likely to raise interest rates again because inflation exceeds the target, and geopolitical events increase inflation risk. Recognizing that the MPC is likely to remain divided, he predicts a moderate and controlled cycle of rate hikes.

Market Sentiment and Forecasts

Despite some optimism related to ongoing mediation efforts, market sentiment remains cautious. Bianca Botess, Managing Director at Citadel Global, reported that investors are closely watching developments in both financial markets and geopolitics. She noted that the S&P 500 closed down 0.19%, while US futures showed gains on Tuesday morning.

Botess added that Asian markets reacted positively to the resumption of mediation efforts between the US and Iran. The MSCI Asia Pacific Index excluding Japan rose by 0.25% on Tuesday, as Asia felt relief from the mediation in the Middle East. She also mentioned that the South African rand continues to follow global investor sentiment, trading steadily at R16.44 against the US dollar, R18.81 against the euro, and R22.15 against the British pound.

Neil Wilson, Investment Strategist at Saxo UK, stated that energy markets remain highly sensitive to the expanding conflict. He noted that the Middle East conflict appears to have expanded and intensified over the weekend. Although oil prices briefly fell after mediation efforts, risks remain heavily skewed towards higher energy prices, inflation, and rates.

Wilson also emphasized that higher oil prices once again put pressure on the broader stock market, leading to a 0.2% drop in the S&P 500. Investors will be closely watching South African inflation data expected on Wednesday, as well as the Reserve Bank's announcement on Thursday, to determine whether slowing inflation or supporting the struggling economy is the priority.